Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
MENU
Back to Top

Live Program

2-3 October 2020The Live Program offers attendees the opportunity to join up to four programs each day, over two days in October. These include two keynote presentations and a choice from six offered symposia each day.  See below for program titles, presenters and times.  Continuing medical education (CME) credit will be available as applicable. There is also an On-Demand option available with additional content.

All live programs will be recorded and available to watch on-demand following the close of the Congress. Participation in the Q&A portion is only available through attending during the posted times below.

Please note CME is only available on the below programs during the times shown.

Click here to registerLive Symposia

All times shown as IPA Secretariat time (Milwaukee, WI US). Local times linked below.
*Program Subject to Change*

  Friday, 2 October                                                                            

0700 (See Local Time)

Opening Keynote: Creating a world that promotes mental health and well being in older people

Presented by: Professor John Beard, University of Sydney, Australia
 

There is good evidence that an older person’s environment is a powerful influence on their mental health and wellbeing.  Norms and stereotypes of age and ageing, access to basic needs such as housing, physical safety, financial security and access to appropriate health and social services are all important contributors.  But most older people live in communities where many of these are lacking and this has been highlighted by the current pandemic.  As the world moves to reinvent itself post COVID, addressing these shortcomings needs to be a priority, and the upcoming DECADE OF HEALTHY AGEING provides an exciting opportunity to ensure governments around the world take concrete action.


Symposia (please note there are six programs in three time slots 0800-1115 with short, 5 minute breaks between)

0805-0905 (1A See Local Time)

The Application of Mass Observation Data in the understanding of Ageing, Dementia and End of Life Care
Presented by: Dr. Louise Taylor, University of Chester, United Kingdom

LEARNING OBJECTIVES:

  1. Enhance appreciation of the ageing process, and growing older in the UK through personal narratives of ageing.
  2. Understand how financial fraud impacts wellbeing in the older population in the UK.
  3. Explore individual choice and preference for end of life care in dementia in the UK.

SPEAKER 1

Prof. Paul Kingston

SPEAKER 2

Dr. Charlotte Eost-Telling

SPEAKER 3

Dr. Jan Bailey

Dementia and primary care – lessons from Europe
Presented by: Prof. Stephen Iliffe, University College London, United Kingdom

PROGRAM DESCRIPTION

The rising prevalence of dementia syndromes in an ageing population is straining the ability of secondary care specialists to fulfill their tasks of timely recognition, diagnosis and support. As a consequence Primary care doctors /General Practitioners will be encouraged to take over some secondary care tasks. This will pose problems for Primary care doctors /General Practitioners, who may not have been trained to work with people with dementia, and who may struggle to incorporate such work into their practice even when trained. This symposium will explore the current and future challenges Primary care doctors /General Practitioners face in recognising and responding to dementia, and outline some lessons from  Ireland, Spain and Portugal.

LEARNING OBJECTIVES:

  1. Become familiar with the challenges Primary care doctors /General Practitioners face in recognising and responding to dementia.
  2. Appreciate the value of case management of people with dementia in primary care, and the potential of  IT solutions to support people with dementia.
  3. Understand primary care interventions in post-diagnostic care pathways.

SPEAKER 1

Dr. Tony Foley

SPEAKER 2

Prof. Manuel A. Franco

SPEAKER 3

Dr. Conceição Balsinha

SPEAKER 4

Prof. Manuel Gonçalves-Pereira


0910-1010 (1B See Local Time)

Risk and Prevention of Dementia: From observation to implementation
Presented by: Dr. Sebastian Koehler, Maastricht University, The Netherlands

SPEAKER 1

Dr. Edo Richard

SPEAKER 2

Dr. Rejko Krüger

SPEAKER 3

Dr. Kay Deckers

SPEAKER 4

Dr. Sebastian Köhler

Young Onset Dementia: prevalence, awareness and service provision
Presented by: Prof. Dr. Raymond Koopmans, Radboud University Medical Center, The Netherlandss

PROGRAM DESCRIPTION

Young Onset Dementia (YOD) is defined as dementia with first symptoms before the age 65-years. People with YOD differ with those with late onset dementia (LOD) in many aspects. This symposium addresses the prevalence and incidence of YOD, service use and differences between YOD and LOD in and course of awareness.

LEARNING OBJECTIVES:

  1. To know that systematic review and meta-analysis of studies on people with YOD showed prevalence increased from 6/100,000 in age range 30-34, to 853/100,000 in age range 60-64
  2. To learn that specialist Young Onset Dementia services have advantages in meeting the distinctive needs of those with young onset dementia
  3. To examine how, over time, people with YOD seem to handle awareness and to know differences in awareness between YOD and LOD.

SPEAKER 1

Stevie Hendriks

The prevalence of young onset dementia: a systematic review and meta-analysis

SPEAKER 2

Prof. Jan R Oyebode

The 'Angela' project survey of service use, costs and satisfaction in Young Onset Dementia

Jan Oyebode is a clinical-academic who has divided her career between clinical psychology roles in the UK NHS and academia. She is currently Professor of Dementia Care at the University of Bradford. Her research focuses on how to support people living with dementia in the community, with special interests in young onset dementia, fronto-temporal dementia and cultural influences on dementia care.

SPEAKER 3

Prof. Marcia Cristina Nascimento Dourado

The differences in the objects of awareness between young and late onset Alzheimer’s disease

Marcia Cristina Nascimento Dourado is a PhD Professor at a Post-graduate Program of Psychiatry and Mental Health of Institute of Psychiatry, Federal University of Rio de Janeiro, Brazil and Coordinator of the Laboratory of Studies on Awareness in Neurocognitive Diseases - LABCONS.

SPEAKER 4

Prof. Dr. Aud Johannessen

Awareness of Dementia and Coping to Preserve Quality of Life: A Five-Year Longitudinal Narrative Study


1015-1125 (1C See Local Time)

Behavioral and Psychological Symptoms of Dementia: Novel Modes of Treatment and Care Delivery
Presented by: Dr. Melanie T. Gentry, Mayo Clinic, United States

PROGRAM DESCRIPTION

As the World Population continues to expand, the number of individuals affected by Alzheimer’s Disease and other Dementias is also rapidly increasing. BPSD has significant negative consequences for morbidity, mortality, and quality of life in those with dementia. Unfortunately, available treatments for BPSD are often limited or inconsistent in their efficacy and prone to severe adverse drug effects such as increased mortality. It is increasingly clear that current approaches are inadequate and novel treatments for BPSD need to be explored and researched. This symposium will draw on the available research literature as well as clinical experiences and case examples to provide up to date information on some of the newest treatment options available for BPSD. Dr. Melanie Gentry will discuss the use of telemedicine and other forms of technology to improve diagnosis and treatment of individuals with BPSD. Dr. Baruth will discuss the rapidly growing interest in the use of medical marijuana and cannabinoids in the management of BPSD. Dr. Lindsey will review the evidence for neuromodulation techniques including electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS).

LEARNING OBJECTIVES:

  1.  Describe how the use of telemedicine and other forms of technology can improve diagnosis and treatment of individuals with BPSD.
  2. Appraise the use of medical marijuana and cannabinoids in the management of BPSD.
  3. Examine the evidence for neuromodulation techniques including electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) for management of BPSD.

SPEAKER 1

Dr. Melanie T. Gentry

Dr. Melanie Gentry is board certified in Psychiatry and Geriatric Psychiatry. She completed her psychiatry residency and geriatric psychiatry fellowship at Harvard Medical School, Massachusetts General and McLean Hospital Programs. She is Assistant Professor in Psychiatry at the Mayo Clinic Alix School of Medicine. She serves as the program director for the Mayo Clinic Geriatric Psychiatry Fellowship. She has clinical and research interests in neurocognitive disorders, psych-oncology, and telemedicine.

SPEAKER 2

Dr. Joshua Baruth

Dr. Baruth is originally from southern Minnesota, and after completing his undergraduate education at the University of Kansas completed both medical school and graduate school at the University of Louisville. He also completed a postdoctoral research fellowship in psychiatry at the Mayo Clinic. Dr. Baruth’s clinical and research interests are related to the aging population, healthcare disparities, and end-of-life issues.

SPEAKER 3

Dr. Jaclyn Lindsey

Dr. Jaclyn Lindsey completed her undergraduate training at the University of Minnesota Duluth. Prior to her medical education at the University of Central Florida College of Medicine, she worked as a nursing assistant at a memory care unit in Minnesota. She is now in her fourth year of psychiatry training at Mayo Clinic and serving as chief resident. Dr. Lindsey plans to complete a fellowship in geriatrics, followed by practice in a community setting, and remaining involved with teaching medical students and residents.

Environmental Influences on the Cognitive and Psychological Well Being of Older Adults with Dementia
Presented by: Dr. William Reichman, Baycrest Health Sciences, Canada

PROGRAM DESCRIPTION

This symposium will review the latest data on the influence of environmental design and its attributes on the cognitive and psychological wellbeing of older adults living with dementia. The presenters will cover the myriad ways in which the physical environment of care can adapt to the changing demands of older adults with sensory, motor and cognitive deficits and foster optimal functioning and quality of life.  The role of emerging technologies will also be reviewed as they complement the contribution of the design of the physical environment to the wellbeing of older adults with cognitive impairment. Information will be offered through a review of the existing research literature as well as case studies that illustrate the impact of environmental modification on fostering wellbeing and minimizing the emergence of the behavioral and psychological symptoms of dementia.  The presenters will represent and integrate sensibilities that have emerged from the fields of architecture, cognitive neuroscience and psychology.

LEARNING OBJECTIVES:

  1. To become familiar with the tenets of the culture change movement and how they are applied in contemporary nursing homes
  2. To learn about how emerging designs for the nursing home environment support culture change-oriented programming
  3. To appreciate the growing role of technology in fostering safety, health and the optimal psychological and cognitive wellbeing of nursing home residents

SPEAKER 1

Mr. L. Bradford Perkins

Mr. Perkins is the co-founder and Chairman of Perkins Eastman, a global architecture firm whose portfolio includes both healthcare and senior living environments. He has worked extensively throughout North America and on projects in over 30 countries across the world.

SPEAKER 2

Prof. Dr. Hilde Verbeek

Hilde Verbeek is a Professor Long-Term Care Environments at Maastricht University, the Netherlands. Her research focuses on the evaluation of innovative design of nursing homes, specifically examining effects and quality of care of small-scale, homelike care environments including green care farms..She has publshed widely in scientific peer-reviewed journals (approx 70 papers), books and book chapters (approx 20) and presents her work to the general public. Her research is characterized through an interdisciplinary perspective, synthesizing and applying evidence from various scientific disciplines both within care related fields (e.g. gerontology, nursing, psychology, geriatrics) as well as outside health care (e.g. architecture, service science) In addition, she is the Vice-Chair of the Living Lab in Ageing and Long-Term Care, a formal and structural collaboration of 7 long-term care organizations (approx. 30,000 clients), 2 vocational training institutes and Zuyd University of Applied Science in the southern part of the Netherlands.

SPEAKER 3

Dr. William E. Reichman

Dr. William E. Reichman is President and Chief Executive Officer of Baycrest, one of the world’s premier centers focused on seniors’ health and residential care, aging brain research, innovation and education. Dr. Reichman is currently President of the International Psychogeriatric Association and has advised the World Health Organization and the governments of Canada, the United States and China on health policy. He is Co-Chair of Canada’s Ministerial Advisory Board on Dementia.


  Saturday, 3 October                                                                            

 

0700 (See Local Time)

Opening Keynote: Suicide in Older Adults: Knowledge, predictions, fears

Presented by: Professor Diego de Leo, Griffith University, Australia

Senior citizens represent a vulnerable segment of the population. Most Covid-19 victims were registered among oldest individuals. Awareness of this threatening situation upset routine; social distancing made anxiety, depression and loneliness more frequent, lockdown created physical de-conditioning, lack of usual checks in therapy and health conditions became almost inevitable etc.: these are just some of the many aspects that were and still are troubling the life of many older adults during the pandemic. Some of these aspects can influence suicidal behavior, and this why it is important to increase vigilance and provide safety networks and assistance to those most in need. This presentation highlights possible links between the pandemic and suicidal behavior in old age. It also provides recommendations to prevent this extreme form of suffering.


Symposia (please note there are six programs in three time slots 0800-1115 with short, 5 minute breaks between)

0805-0905 (2A See Local Time)

The Role of Assistive Technologies in Promoting Social Health and Well-being
Presented by: Dr. Franka Meiland, Amsterdam UMC, The Netherlands

LEARNING OBJECTIVES:

  1. Learn how to evaluate usability and acceptability of tablet interventions for persons with dementia
  2. Learn about the potential of e-health interventions to improve social health and well-being of people with dementia and their carers
  3. Learn how a scoping review may help to define the potential of delivering technology-based psychosocial interventions targeting loneliness in dementia.

SPEAKER 1

Harleen Rai

The individual Cognitive Stimulation Therapy (iCST) application for people with dementia and carers: a feasibility randomized controlled trial

Harleen Kaur Rai is a PhD student and a Marie Sklodowska-Curie alumnus (2016-2019) at the University of Nottingham where she developed and evaluated Thinkability: a touch-screen version of iCST for people with dementia and carers. She previously worked for the World Health Organisation on two occasions (2015-2016) where she contributed to the development of iSupport: an online tool for carers of people with dementia. She completed her BSc. in Psychology (2013) and her MSc. in Clinical and Cognitive Neuropsychology at VU University in Amsterdam (2015).

SPEAKER 2

K.M. Beentjes

Results of a Feasibility Trial into the FindMyApps Program: a Tablet Computer-Based intervention to promote Social Health of People with Dementia

Kim Beentjes is a Junior Researcher at the department of Psychiatry, Amsterdam UMC (location VUmc) with a background in Public Health and Public Policy. She is the executive researcher of FindMyApps, which is a tablet-based selection tool for people with dementia and their caregivers that aims to improve their self-management and participation in meaningful activities.

SPEAKER 3

Kübra Beliz Budak

Loneliness and Technology: Can technology help reduce loneliness in dementia?

Kübra Beliz Budak is a Psychologist by training. She is interested in implementation processes of Active Assistive Living (AAL) technology to enhance psychosocial well-being of people with dementia. As a PhD candidate she will be studying the gap between psychosocial well-being interventions and the possibilities of delivering these with AAL devices. Her earlier work was mainly concerned with cancer patients with depression and whether psychosocial interventions would benefit them. Since 2019, she is a  DISTINCT fellow at DZNE Witten, aiming to find out ways of better living for people with dementia with the help of technology. DISTINCT is a Marie Sklodowska Curie European funded training and research network.

Introductions by

Franka Meiland

Franka Meiland (PhD) is health psychologist, teacher and senior researcher at the department of Medicine for Older people at Amsterdam UMC, location VUmc, the Netherlands. Her focus is on development evaluation and implementation of psychosocial (eHealth) interventions in dementia. She is taskforce leader of the Taskforce Assistive technology of the European INTERDEM group on timely and effective psychosocial interventions in dementia.

New trends in aging and dementia in Latin America and the Caribbean Region
Presented by: Dr. Daisy Acosta, 10/66 Dementia Research Group, Dominican Republic

PROGRAM DESCRIPTION

Alzheimer’s disease (AD) and dementia has emerged as a significant societal issue and a global priority. The prevalence of dementia is rising more rapidly in low- and middle-income countries (LMIC) than in high income countries. Yet, knowledge of dementia risk factors is dominated by research from high income countries (HIC), which cannot be readily translated to LMIC. Latin American countries (LAC) have unique challenges related to dementia, including rapid aging population, high admixture degree and risk factors profile, which influence the prevalence and presentation of dementia. Several epidemiological studies during the past decade have shown a rapid increase of dementia in LAC, but the impact of genetic, protective and risk factors remain poorly understood. This research session will feature a series of short and engaging talks about new trends of dementia in the region and will answer key questions regarding dementia determinants and consequences in Hispanic populations. Participants will be first introduced to the aging process in LAC, prevalence and incidence of dementia within the region. The second presentation will report on genetics of Alzheimer disease in Hispanic populations. The third presenter will discuss the complexities of dementia multimorbidity and the impact of neuropsychiatric symptoms. The fourth presenter will discuss about Nationals and Regional Strategies to address dementia and reflects on recommendations and future directions for the region.  All presentations will be based on findings from multiple research projects across the region. Furthermore, presenters will be extended comparison to Non-Hispanics whites and Hispanics populations living in US which allows cross countries/society comparisons. Overall, new information about dementia will be shared with the audience. Attendees will be able to identify the unique genetic and social determinants that drive AD in LAC. Recommendations will be given for preventive strategies tailored to LMIC. The findings to be shared will be essential for building evidence-based interventions that achieve the goals of the National Plan to Address Alzheimer’s Disease.               

LEARNING OBJECTIVES:

  1. Determine the impact of the aging process and dementia in Latin America.
  2. Identify the unique genetic and social determinants that drive AD in Latin America.
  3. Evaluate problem-solving strategies, and develop science-based solutions to address the impact of Dementia in Latin America.

SPEAKER 1

Dr. Juan de J. Llibre Rodríguez

Aging and dementia in Latin America      

Juan J. Llibre Rodriguez is Professor of Internal Medicine and Geriatric Medicine at the Medical University of Havana, Finlay Albarran (School of Medicine). He funded the Cuban Section of Alzheimer’s disease in 1996. He obtained his MD in 1983 and his PhD in 1998 from the Medical University of Havana and a second PhD in Epidemiology at the King College of London in 2012. He was awarded with the title Doctor in Sciences (DSc) in 2014. Over the past decades, Dr Llibre´s research focused on the epidemiology of dementia (in particular Alzheimer’s disease), and other NCDs in older Cubans, and the study of vascular factors, APOE and lifestyle factors in the etiology of dementia. He is the Principal investigator of the 10/66 International Dementia Research Group in Cuba and also the Cuban Aging and Alzheimer’s Study a large prospective cohort study on chronic diseases and dementia in the elderly .He has coordinated a multidisciplinary team and Dementia Unit since 1990 in Havana and also several courses and training address to professional and caregivers of people with dementia. Dr. Llibre founded the MSc in Dementia Care and Research at the Medical University of Havana and a National Postgraduate Diploma in Dementia. He has been published more than 85 articles in the last 10 years and 3 books on dementia and mental health. Juan J. Llibre is an Official member of Cuban Sciences Academic. He received the Annual Awards of Cuban Academy of Sciences, 2014 and the Annual Award of Cuban Health in 2011, 2015 and 2018. He has been extensively involved in dissemination of research for public awareness and public policy in Cuba and Latin America. 

SPEAKER 2

Dr. Jorge J Llibre-Guerra

Alzheimer Disease and genetics in Hispanic Populations 

Jorge Llibre completed his medical training at the Medical University of Havana, followed by residency in neurology at the National Institute of Neurology, where he was Chief Resident. He has received awards from the Ministry of Health, American Academy of Neurology, World Federation of Neurology, and Havana School of Medicine. University College London awarded him a training experience on Global Mental Health. Llibre created the Cognitive and Behavior Research Unit at the National Institute of Neurology in order to help meet the needs of the aging population and was tapped to help in the National Strategy for Dementia and Alzheimer Disease.  In 2016, he joined the Global Brain Health Institute at the Memory and Aging Center, UCSF, where received fellowship training in Behavioral Neurology and Global Mental Health. Since 2018, Dr.Llibre joined the Dominantly Inherited Alzheimer Network (DIAN) and has been leading research efforts to develop new DIAN centers in Latin America. His research focuses on health disparities and dementia. Recent work focuses on the influence of life course behavioral risk/protective factors on AD onset, cognitive decline, and biomarker rate of change. Llibre has research funding from the World Federation of Neurology and Alzheimer Association.

SPEAKER 3

Dr. Daisy Acosta

Dementia multimorbidity and neuropsychiatric symptoms across the disease

Daisy Acosta completed her medical training at at Universidad Nacional Pedro Henriquez Ureña (UNPHU) in Santo Domingo, Dominican Republic. Dr. Acosta continued training in geriatric psychiatry at Saint Francis General Hospital in Pittsburgh, Pennsylvania, where she received board certification by the American board of psychiatry and neurology, geriatric psychiatry and forensic medicine. Her research and professional life focus on Alzheimer’s disease, especially in neuro neuropsychiatric symptoms; she has a large clinical practice based in The Dominican Republic where she is very well known for her dedication to the care and treatment of people with dementia. Dr. Acosta is co-founder and Ad Vitam medical advisor, head of the Dominican Alzheimer’s Association and past Chairperson of Alzheimer Disease International (ADI). She is the author of several scientific articles published in national and international journals and co-author of several books on dementia in the Latino American region. Dr. Acosta has led the 10/66 Dementia Research Group center in the Dominican Republic for more than 15 years, and is an associate professor of medicine at Universidad Nacional Pedro Henriquez Ureña (UNPHU). She holds a tittle in the National career of Investigation Science Technology and Innovation and is the founder of the National Brain Bank in the Dominican Republic.      

SPEAKER 4

Dr. Ivonne Z Jimenez-Velazquez

Alzheimer’s Research in Latin America: National Strategies and Future Plans to address dementia.

Ivonne Jimenez-Velazquez is a Professor at the University of Puerto Rico. She Completed Doctor of Medicine at the School of Medicine-UPR, she interned at the Regional Hospital of Caguas and three years of Internal Medicine in the University Hospital, being then an Instructor in the Department of Medicine. She worked as an adjunct professor at Mount Sinai before returning to the department of medicine at University of Puerto Rico School of Medicine where she became a full professor.  Dr.Jimenez is a member of the American Geriatrics Society, Association of Professors of Medicine, American Association for Geriatric Psychiatry and  serves as Chair of the Internal Medicine Department, Medical Sciences Campus, University of Puerto Rico in San Juan. Her research Interests are Geriatrics, Clinical Research, Epidemiology, Biostatistics, Psychiatry. She has been a researcher or co-researcher in 12 scientific research studies.


0910-1010 (2B See Local Time)

Novel Treatments for Resistant Depression: Comparison of older and younger patients
Presented by: Dr. William M. McDonald, Emory University, United States

PROGRAM DESCRIPTION

SPEAKER 1

Dr. George Petrides

SPEAKER 2

Dr. Collin Reiff

SPEAKER 3

Dr. Patricio Riva Posse

Investigations of Risk, Resilience and Novel Therapeutics of Late Life Neuropsychiatric Disease
Presented by: Dr. Gwenn Smith, Johns Hopkins University, United States

LEARNING OBJECTIVES:

  1. To learn about the altered dendritic inhibition across neuropsychiatric and age-related brain disorders
  2. To learn about the role of cortical microcircuit
  3. To learn about the role of increasing dendritic inhibition as a therapeutic modality for cellular and cognitive deficits in depression and during aging
  4. To identify genetic correlates of risk and resilience to psychosis in Alzheimer disease.

SPEAKER 1

Dr. Etienne Sibille

Dr. Sibille is a neuroscientist with 25 years of expertise in investigating the biological bases of neuropsychiatric disorders. His group has provided key evidence in support of several major hypotheses for depression. He has also demonstrated that the molecular changes that occur in the brain during depression are closely related to brain aging.
Building on breakthrough findings from his group over the past 10 years, he has now developed novel therapeutics that he intends to bring to the clinic for treating and preventing cognitive symptoms in depression and in age-related disorders, but also for healing the brain cells that are affected by these disorders.

SPEAKER 2

Dr. Robert Sweet

Dr. Sweet is UPMC Endowed Professor of Psychiatric Neuroscience and Professor of Neurology at the University of Pittsburgh. He is Director of the Clinical Core of the University of Pittsburgh Alzheimer Disease Research Center, and Directs an NIMH-funded postdoctoral training program emphasizing Translational Neuroscience Research. Dr. Sweet’s honors include NARSAD Distinguished Investigator Grant from the Brain & Behavior Research Foundation; American Association for Geriatric Psychiatry’s Distinguished Scientist Award, and; The Geriatric Research Award from the American College of Psychiatrists. Dr. Sweet’s lab investigates the mechanisms leading to the joint liability to cognitive and psychotic symptoms in Alzheimer disease and schizophrenia, using a variety of approaches including genomic, human brain tissue, genetic animal model, and in vitro studies. 

SPEAKER 3

Dr. Helen Lavretsky

Dr. Helen Lavretsky is a Professor of Psychiatry at UCLA, with federally funded research program in geriatric depression and integrative mental health. She directs the Late-life mood, stress and wellness r and the Integrative Psychiatry research programs. She is a recipient of the Career Development award from NIMH and the NCCIH, and other prestigious research awards. Her current research studies include investigations of psychopharmacological treatment of geriatric depression, mild cognitive impairment and the use of Tai Chi and yoga for treatment and prevention of late-life mood and cognitive disorders. She is the Distinguished Fellow of the American Psychiatric Association and the Fellow of the American College of Neuropsychopharmacology, and the recipient of the Distinguished Investigator awards for research in geriatric psychiatry from the American College of Psychiatrists, American Psychiatric Association, and the American Association for Geriatric Psychiatry. 


1015-1115 (2C See Local Time)

Surface neuromodulation (TMS and tDCS) for therapy of cognitive and psychiatric disorders
Presented by: Dr. Howard Chertkow, Baycrest Health Sciences, Canada

LEARNING OBJECTIVES:

  1. The range of neuromodulation techniques
  2. How tDCS and rTMS are different
  3. The clinical potential of tDCS as treatment for AD and FTD
  4. Basic determinants of stroke rehabilitation of motor and language abilities
  5. Evidence for recovery based on contralateral hemisphere suppression.
  6. Evidence for therapeutic efficacy of rTMS in stroke recovery.
  7. What are the differences between  neuromodulation technizues such as magnetic seizure therapy (MST), repetitive transcranial magnetic stimulation (rTMS), and deep rTMS).
  8. What is the range of neuropsychiatric conditions shown to respond to neuromodulation therapy?
  9. What is the evidence that rTMS can benefit late-life depression?

SPEAKER 1

Dr. Howard Chertkow

tDCS in the treatment of neurodegenerative diseases

Dr. Chertkow is a cognitive neurologist and director of the new Kimel Central for Brain Health at the Baycrest Health Sciences  Centre. He is also Senior Scientist and Chair in Cognitive Neurology and Innovation at Baycrest’s Rotman Research Institute and a Professor in the Dept. of Medicine (Neurology) at University of Toronto. His major areas of research interest include early diagnosis of Alzheimer’s Disease, and therapy of dementia using neuromodulation approaches such as transcranial direct current stimulation. Dr. Chertkow is Scientific Director for the Canadian Consortium on Neurodegeneration in Aging (CCNA),  a national organization established by the Canadian government via CIHR and partners.

SPEAKER 2

Prof. Alex Thiel

Neuromodulation and rTMS in treatment and rehabilitation of stroke

Dr. Thiel is a neurologist and neuroscientist, who does translational research in post-stroke recovery using brain imaging and non-invasive brain stimulation methods. His neuroplasticity research program was established around the stroke unit at the Jewish General Hospital in Montreal. This combination of an acute stroke unit with a non-invasive brain stimulation and imaging laboratory is the first of its kind in Canada, constituting a research facility at the patient’s bedside. It was awarded the HSFQ Stroke Excellence Award. He has been instrumental in the creation  of a clinical trial platform on the new integrated neuroscience unit at the Jewish General Hospital that facilitates the systematic evaluation of different stimulation modalities and imaging methods in a clinical context.

SPEAKER 3

Prof. Daniel Blumberger

rTMS in the treatment of late-life depression

Dr. Daniel Blumberger is a Clinician Scientist in the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health (CAMH) at University of Toronto. He is the Medical Head and Co-Director of the Temerty Centre for Therapeutic Brain Intervention at CAMH. He is a subspecialist in geriatric psychiatry and also heads the Late-Life Mood Disorders Clinic. Dr. Blumberger’s research focuses on the use of brain stimulation therapies for refractory psychiatric disorders. His main research focuses on clinical intervention trials of novel treatments, and understanding the neurophysiology of treatment-resistant depression across the lifespan. His research has been funded by the Canadian Institutes of Health Research, National Institute of Health, Brain Canada, Weston Brain Institute, Brain and Behavior Research Foundation, and Patient- Centered Outcomes Research Institute.

Teaching and Training Old Age Psychiatry around the world
Presented by: Dr. Horácio J. Firmino, Centro Hopitalar e Universitário de Coimbra; Portugal

SPEAKER 1

Dr. Carlos A. de Mendonça Lima

SPEAKER 2

Dr. Manuel Sanchez Perez

SPEAKER 3

Prof. Manuel Teixeira Verissimo

Click here to register

Acknowledgements

Acadia Pharmaceuticals Otsuka Pharmaceuticals Cambridge University Press Avanir Pharmaceuticals
CORPORATE COUNCILS